Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Astrocytes in mouse amygdala encode emotional state
The glial cells’ activity reliably tracks with freezing, hesitancy and other behaviors reminiscent of anxiety.
Astrocytes in mouse amygdala encode emotional state
The glial cells’ activity reliably tracks with freezing, hesitancy and other behaviors reminiscent of anxiety.
Data duplications flagged in highly cited gut-brain studies
The duplications are a product of “inadvertent errors,” the authors say.
Data duplications flagged in highly cited gut-brain studies
The duplications are a product of “inadvertent errors,” the authors say.
Infant Brain Imaging Study findings, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 23 March.
Infant Brain Imaging Study findings, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 23 March.